A PYMNTS Company

US: AbbVie to pay $1.6B for failed Shire deal

By  |  October 21, 2014

Just days after pharmaceutical conglomerate AbbVie said it was reconsidering its plans to acquire Shire due to recent crackdowns on inversion mergers, reports say the merger is officially cancelled, and that AbbVie will pay a breakup fee to Shire.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    AbbVie had planned to acquire Shire for $55 billion in a takeover that would also relocate AbbVie’s tax bracket overseas to the UK. The merger would result in lower taxes for AbbVie.

    But authorities in both the US and EU have recently upped criticism over such mergers; the European Commission is currently investigating whether they constitute illegal state aid, and the US introduced new limitations on the tax benefits corporations can enjoy through such mergers.

    AbbVie confirmed that it has cancelled plans to acquire Shire and said it will pay the $1.64 billion breakup fee previously agreed upon.

    Full content: CNBC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.